| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.17 | 5e-07 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.15 | 7e-05 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | 0.14 | 8e-05 |
| mRNA | PHA-793887 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0001 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0001 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.19 | 0.0003 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.17 | 0.0003 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0005 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0006 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0007 |